This document summarizes a cost-effectiveness analysis comparing biphasic insulin aspart 70/30 twice daily versus insulin glargine once daily for type 2 diabetes patients. The analysis found that biphasic insulin aspart was more effective and less costly over patient lifetimes. A sensitivity analysis showed that varying key parameters did not significantly impact results. The conclusions were appropriately based on an incremental cost-effectiveness analysis.